Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Otsuka Pharmaceutical Development & Commercialization, Inc.

Clinicaltrial registered29 Oct 2026

Otsuka Pharmaceutical Development & Commercialization, Inc.

29 Oct 2026: Trial registered · Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
29 Oct 2026
Title
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07904806
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Otsuka Pharmaceutical Development & Commercialization, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Otsuka Pharmaceutical Development & Commercialization, Inc. in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.